Stallion India Fluorochemicals Ltd
Stallion India Fluorochemicals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #9 of 71 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
FY26 revenue guidance is INR 430 crores, with PAT guidance of INR 40 crores. Stallion India Fluorochemicals targets a 30-35% CAGR over the next three years driven by backward integration, higher value products, and margin expansion of 3-4%. - FY26 revenue guidance is INR 430 crores with PAT guidance of INR 40 crores. - For FY27, expected revenue of INR 550 crores from new facilities plus current business, with PAT between INR 180-200 crores combining all operations. - New R32 plant (10,000 MT capacity) is expected to achieve 50% production in first six months generating approx.
From Stallion India Fluorochemicals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY26 revenue guidance is INR 430 crores, with PAT guidance of INR 40 crores.
- Expect production start of R32 plant with six months production from October 2026 generating about INR 275 crores revenue and INR 66 crores PAT in first year.
- FY27 revenue target is INR 550 crores and PAT INR 132 crores, combining current business and new facilities.
- Next year projected turnover around INR 950 crores with full-year R32 production and growth from helium and speciality gases.
- Long-term (5 years) target for helium and speciality gases revenue is INR 200 crores.
2 more points from Stallion India Fluorochemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Stallion India Fluorochemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Raising INR 364 crores through a rights issue for the R32 plant expansion to 10,000 metric tons capacity.
- CapEx for R32 plant doubled from INR ~200 crores to INR 364 crores due to scale-up.
- Helium facilities at Khalapur and Mambattu being set up with a total CapEx of INR 15-20 crores funded through internal accruals.
- Expansion involves setting up integrated chemical process plants with future phases including by-product commercialization and HFO plant.
2 more points from Stallion India Fluorochemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Stallion India Fluorochemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Stallion India Fluorochemicals Ltd's call on order book
Create a free account to keep reading this call
Stallion India Fluorochemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹110 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Stallion India Fluorochemicals Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio Solutions Ltd (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Stallion India Fluorochemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Stallion India Fluorochemicals Ltd Q3 FY26 results?
FY26 revenue guidance is INR 430 crores, with PAT guidance of INR 40 crores. Stallion India Fluorochemicals targets a 30-35% CAGR over the next three years driven by backward integration, higher value products, and margin expansion of 3-4%. - FY26 revenue guidance is INR 430 crores with PAT guidance of INR 40 crores. - For FY27, expected revenue of INR 550 crores from new facilities plus current business, with PAT between INR 180-200 crores combining all operations. - New R32 plant (10,000 MT capacity) is expected to achieve 50% production in first six months generating approx.
What is Stallion India Fluorochemicals Ltd share price analysis?
Stallion India Fluorochemicals Ltd currently shows a neutral. The stock trades at a P/E of 51.3 with a market cap of ₹2,668 Cr. Investors should review the full earnings analysis for detailed insights.
Is Stallion India Fluorochemicals Ltd planning capital expenditure?
Raising INR 364 crores through a rights issue for the R32 plant expansion to 10,000 metric tons capacity.
Keep Stallion India Fluorochemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.